Development of live attenuated influenza vaccines against pandemic influenza strains

Kathleen L. Coelingh, Catherine J. Luke, Hong Jin, Kawsar R. Talaat

Research output: Contribution to journalReview article

Abstract

Avian and animal influenza viruses can sporadically transmit to humans, causing outbreaks of varying severity. In some cases, further human-to-human virus transmission does not occur, and the outbreak in humans is limited. In other cases, sustained human-to-human transmission occurs, resulting in worldwide influenza pandemics. Preparation for future pandemics is an important global public health goal. A key objective of preparedness is to gain an understanding of how to design, test, and manufacture effective vaccines that could be stockpiled for use in a pandemic. This review summarizes results of an ongoing collaboration to produce, characterize, and clinically test a library of live attenuated influenza vaccine strains (based on Ann Arbor attenuated Type A strain) containing protective antigens from influenza viruses considered to be of high pandemic potential.

Original languageEnglish (US)
Pages (from-to)855-871
Number of pages17
JournalExpert review of vaccines
Volume13
Issue number7
DOIs
StatePublished - Jul 2014

Keywords

  • LAIV
  • intranasal influenza vaccine
  • pandemic influenza vaccine

ASJC Scopus subject areas

  • Immunology
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Development of live attenuated influenza vaccines against pandemic influenza strains'. Together they form a unique fingerprint.

  • Cite this